Cargando…

Imaging Aβ and tau in early stage Alzheimer’s disease with [(18)F]AV45 and [(18)F]AV1451

BACKGROUND: AD is a progressive neurodegenerative disorder that is associated with the accumulation of two different insoluble protein aggregates, Aβ plaques and hyperphosphorylated tau. This study aimed to investigate the optimal acquisition and quantification of [(18)F]AV45 and [(18)F]AV1451 to im...

Descripción completa

Detalles Bibliográficos
Autores principales: Firouzian, Azadeh, Whittington, Alex, Searle, Graham E., Koychev, Ivan, Zamboni, Giovanna, Lovestone, Simon, Gunn, Roger N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834417/
https://www.ncbi.nlm.nih.gov/pubmed/29500717
http://dx.doi.org/10.1186/s13550-018-0371-y
_version_ 1783303636281982976
author Firouzian, Azadeh
Whittington, Alex
Searle, Graham E.
Koychev, Ivan
Zamboni, Giovanna
Lovestone, Simon
Gunn, Roger N.
author_facet Firouzian, Azadeh
Whittington, Alex
Searle, Graham E.
Koychev, Ivan
Zamboni, Giovanna
Lovestone, Simon
Gunn, Roger N.
author_sort Firouzian, Azadeh
collection PubMed
description BACKGROUND: AD is a progressive neurodegenerative disorder that is associated with the accumulation of two different insoluble protein aggregates, Aβ plaques and hyperphosphorylated tau. This study aimed to investigate the optimal acquisition and quantification of [(18)F]AV45 and [(18)F]AV1451 to image Aβ and tau, respectively, in subjects with AD. Fifteen subjects with early stage AD underwent a T1-weighted structural MRI and two dynamic PET scans to image Aβ (60 min, [(18)F]AV45) and tau (120 min, [(18)F]AV1451). Both dynamic BP(ND) and static SUVR outcome measures were calculated and compared for 12 out of 15 subjects who completed 60 min of the Aβ PET scan and at least 110 min of the tau PET scan. The SRTM and reference Logan graphical analysis were applied to the dynamic data to estimate regional BP(ND) values and SUVR ratios from the static data. Optimal acquisition windows were explored for both the dynamic and static acquisitions. In addition, the spatial correlation between regional Aβ and tau signals was explored. RESULTS: Both the SRTM and graphical analysis methods showed a good fit to the dynamic data for both Aβ and tau dynamic PET scans. Mean regional BP(ND) estimates became stable 30 min p.i. for [(18)F]AV45 and 80 min p.i. for [(18)F]AV1451. Time stability analysis of static SUVR data showed that the outcome measure starts to become stable for scan windows of 30–50 min p.i. for [(18)F]AV45 and 80–100 min p.i. for [(18)F]AV1451. The results from these time windows correlated well with the results from the full dynamic analysis for both tracers (R(2) = 0.74 for [(18)F]AV45 and R(2) = 0.88 for [(18)F]AV1451). There was a high correlation between amyloid uptake estimate using both dynamic analysis methods in thalamus and tau uptake in thalamus, hippocampus and amygdala. CONCLUSIONS: Short static PET scans at appropriate time windows provided SUVR values which were in reasonable agreement with BP(ND) values calculated from dynamic scans using SRTM and reference Logan. These simplified methods may be appropriate for classification and intervention studies, although caution should be employed when considering interventional studies where blood flow and extraction could change.
format Online
Article
Text
id pubmed-5834417
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-58344172018-03-13 Imaging Aβ and tau in early stage Alzheimer’s disease with [(18)F]AV45 and [(18)F]AV1451 Firouzian, Azadeh Whittington, Alex Searle, Graham E. Koychev, Ivan Zamboni, Giovanna Lovestone, Simon Gunn, Roger N. EJNMMI Res Original Research BACKGROUND: AD is a progressive neurodegenerative disorder that is associated with the accumulation of two different insoluble protein aggregates, Aβ plaques and hyperphosphorylated tau. This study aimed to investigate the optimal acquisition and quantification of [(18)F]AV45 and [(18)F]AV1451 to image Aβ and tau, respectively, in subjects with AD. Fifteen subjects with early stage AD underwent a T1-weighted structural MRI and two dynamic PET scans to image Aβ (60 min, [(18)F]AV45) and tau (120 min, [(18)F]AV1451). Both dynamic BP(ND) and static SUVR outcome measures were calculated and compared for 12 out of 15 subjects who completed 60 min of the Aβ PET scan and at least 110 min of the tau PET scan. The SRTM and reference Logan graphical analysis were applied to the dynamic data to estimate regional BP(ND) values and SUVR ratios from the static data. Optimal acquisition windows were explored for both the dynamic and static acquisitions. In addition, the spatial correlation between regional Aβ and tau signals was explored. RESULTS: Both the SRTM and graphical analysis methods showed a good fit to the dynamic data for both Aβ and tau dynamic PET scans. Mean regional BP(ND) estimates became stable 30 min p.i. for [(18)F]AV45 and 80 min p.i. for [(18)F]AV1451. Time stability analysis of static SUVR data showed that the outcome measure starts to become stable for scan windows of 30–50 min p.i. for [(18)F]AV45 and 80–100 min p.i. for [(18)F]AV1451. The results from these time windows correlated well with the results from the full dynamic analysis for both tracers (R(2) = 0.74 for [(18)F]AV45 and R(2) = 0.88 for [(18)F]AV1451). There was a high correlation between amyloid uptake estimate using both dynamic analysis methods in thalamus and tau uptake in thalamus, hippocampus and amygdala. CONCLUSIONS: Short static PET scans at appropriate time windows provided SUVR values which were in reasonable agreement with BP(ND) values calculated from dynamic scans using SRTM and reference Logan. These simplified methods may be appropriate for classification and intervention studies, although caution should be employed when considering interventional studies where blood flow and extraction could change. Springer Berlin Heidelberg 2018-03-02 /pmc/articles/PMC5834417/ /pubmed/29500717 http://dx.doi.org/10.1186/s13550-018-0371-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Firouzian, Azadeh
Whittington, Alex
Searle, Graham E.
Koychev, Ivan
Zamboni, Giovanna
Lovestone, Simon
Gunn, Roger N.
Imaging Aβ and tau in early stage Alzheimer’s disease with [(18)F]AV45 and [(18)F]AV1451
title Imaging Aβ and tau in early stage Alzheimer’s disease with [(18)F]AV45 and [(18)F]AV1451
title_full Imaging Aβ and tau in early stage Alzheimer’s disease with [(18)F]AV45 and [(18)F]AV1451
title_fullStr Imaging Aβ and tau in early stage Alzheimer’s disease with [(18)F]AV45 and [(18)F]AV1451
title_full_unstemmed Imaging Aβ and tau in early stage Alzheimer’s disease with [(18)F]AV45 and [(18)F]AV1451
title_short Imaging Aβ and tau in early stage Alzheimer’s disease with [(18)F]AV45 and [(18)F]AV1451
title_sort imaging aβ and tau in early stage alzheimer’s disease with [(18)f]av45 and [(18)f]av1451
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834417/
https://www.ncbi.nlm.nih.gov/pubmed/29500717
http://dx.doi.org/10.1186/s13550-018-0371-y
work_keys_str_mv AT firouzianazadeh imagingabandtauinearlystagealzheimersdiseasewith18fav45and18fav1451
AT whittingtonalex imagingabandtauinearlystagealzheimersdiseasewith18fav45and18fav1451
AT searlegrahame imagingabandtauinearlystagealzheimersdiseasewith18fav45and18fav1451
AT koychevivan imagingabandtauinearlystagealzheimersdiseasewith18fav45and18fav1451
AT zambonigiovanna imagingabandtauinearlystagealzheimersdiseasewith18fav45and18fav1451
AT lovestonesimon imagingabandtauinearlystagealzheimersdiseasewith18fav45and18fav1451
AT gunnrogern imagingabandtauinearlystagealzheimersdiseasewith18fav45and18fav1451
AT imagingabandtauinearlystagealzheimersdiseasewith18fav45and18fav1451